What question did this study set out to answer?

To review the biochemical characteristics and regulatory mechanisms of platelet phosphodiesterases and examine how cyclic nucleotide signaling cross-talk informs the development of antithrombotic therapies.

January 1, 1999Thrombosis and Haemostasis

Cyclic Nucleotides and Phosphodiesterases in Platelets

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

NDNatalie DickinsonUniversity of the West of Scotland EJElliott JangHamilton Regional Laboratory Medicine Program RHRichard P. HaslamRothamsted Research

Discussion

Member takes

Overview

Provides mechanistic overview of platelet PDEs; leaves open translation of cAMP/cGMP modulators into clinical antithrombotic strategies.

Key Points

To review the biochemical characteristics and regulatory mechanisms of platelet phosphodiesterases and examine how cyclic nucleotide signaling cross-talk informs the development of antithrombotic therapies.
Narrative synthesis of pharmacological and biochemical literature on platelet cAMP and cGMP production and downstream kinase signaling.
Evaluation of phosphodiesterase (PDE) enzymatic regulation, cAMP and cGMP hydrolysis, and inhibitor pharmacodynamics.
Agonists such as prostacyclin and nitric oxide stimulate cAMP and cGMP synthesis respectively, which activate PKA and PKG to prevent platelet aggregation.
Phosphodiesterases act as crucial negative regulators by degrading cyclic nucleotides to terminate inhibitory signaling pathways in platelets.
Cross-talk between cAMP and cGMP pathways occurs via cGMP-mediated regulation of cAMP phosphodiesterases and kinase cross-activation.

Cite This Study

Dickinson et al. (1999) studied this question.

synapsesocial.com/papers/6a768d1f232067cbf2ec19bc https://doi.org/10.1055/s-0037-1615861

View Full Paper

Ask AI

Bookmark

January 1, 1999Thrombosis and Haemostasis

Cyclic Nucleotides and Phosphodiesterases in Platelets

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

NDNatalie DickinsonUniversity of the West of Scotland EJElliott JangHamilton Regional Laboratory Medicine Program RHRichard P. HaslamRothamsted Research

Discussion

Member takes

Overview

Provides mechanistic overview of platelet PDEs; leaves open translation of cAMP/cGMP modulators into clinical antithrombotic strategies.

Key Points

To review the biochemical characteristics and regulatory mechanisms of platelet phosphodiesterases and examine how cyclic nucleotide signaling cross-talk informs the development of antithrombotic therapies.
Narrative synthesis of pharmacological and biochemical literature on platelet cAMP and cGMP production and downstream kinase signaling.
Evaluation of phosphodiesterase (PDE) enzymatic regulation, cAMP and cGMP hydrolysis, and inhibitor pharmacodynamics.
Agonists such as prostacyclin and nitric oxide stimulate cAMP and cGMP synthesis respectively, which activate PKA and PKG to prevent platelet aggregation.
Phosphodiesterases act as crucial negative regulators by degrading cyclic nucleotides to terminate inhibitory signaling pathways in platelets.
Cross-talk between cAMP and cGMP pathways occurs via cGMP-mediated regulation of cAMP phosphodiesterases and kinase cross-activation.

Cite This Study

Dickinson et al. (1999) studied this question.

synapsesocial.com/papers/6a768d1f232067cbf2ec19bc https://doi.org/10.1055/s-0037-1615861

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark